Related references
Note: Only part of the references are listed.Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
Mark J. Truty et al.
ANNALS OF SURGERY (2021)
Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study
Tatsunori Miyata et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial
Davendra P. S. Sohal et al.
JAMA ONCOLOGY (2021)
Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma
Keinosuke Ishido et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2021)
Completion of adjuvant therapy in patients with resected pancreatic cancer
Danielle K. DePeralta et al.
HPB (2020)
Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection?
Atsushi Oba et al.
LANGENBECKS ARCHIVES OF SURGERY (2020)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort
Marta Herreros-Villanueva et al.
MOLECULAR BIOLOGY REPORTS (2020)
Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis
Mao Ye et al.
HPB (2020)
Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
Syed A. Ahmad et al.
ANNALS OF SURGERY (2020)
Clinical implications of the serum CA19-9 level in biological borderline resectability and biological downstaging in the setting of preoperative chemoradiation therapy for pancreatic cancer
Hidenori Takahashi et al.
PANCREATOLOGY (2020)
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
Vincent P. Groot et al.
ANNALS OF SURGERY (2019)
A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?
Toru Nakamura et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2019)
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma
Paula Ghaneh et al.
ANNALS OF SURGERY (2019)
Impact of resection margin status on recurrence and survival in pancreatic cancer surgery
W. S. Tummers et al.
BRITISH JOURNAL OF SURGERY (2019)
A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer
Imlimaong Aier et al.
CANCER EPIDEMIOLOGY (2019)
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
Michiaki Unno et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis
Alison Bradley et al.
PLOS ONE (2019)
Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma
Wataru Izumo et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Global Patterns and Trends in Pancreatic Cancer Incidence Age, Period, and Birth Cohort Analysis
Ganfeng Luo et al.
PANCREAS (2019)
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
Fuyuhiko Motoi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer
Sung Jun Ma et al.
JAMA NETWORK OPEN (2019)
Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
E. Versteijne et al.
BRITISH JOURNAL OF SURGERY (2018)
A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence
Hiroshi Kurahara et al.
PANCREAS (2018)
CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients
Nicolas Santucci et al.
PANCREATOLOGY (2018)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients
Sang Hyun Shin et al.
SURGERY (2018)
Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer
Cinthya Y. Lowder et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma
Shigeki Nakagawa et al.
PANCREAS (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Andrew McGuigan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer
Shuji Suzuki et al.
EUROPEAN SURGICAL RESEARCH (2018)
Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection
Yuichi Hosokawa et al.
DIGESTIVE SURGERY (2017)
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
Stefan Heinrich et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study
Jin-Young Jang et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Early versus delayed initiation of adjuvant treatment for pancreatic cancer
Hyoung Woo Kim et al.
PLOS ONE (2017)
Preoperative predictors for early recurrence of resectable pancreatic cancer
Kohei Nishio et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2017)
Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies
Han-Xiang Zhan et al.
CANCER MEDICINE (2017)
Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons
Su Kah Goh et al.
ANZ JOURNAL OF SURGERY (2017)
Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer
S. Yamashita et al.
BRITISH JOURNAL OF SURGERY (2017)
Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection
Franz Mierke et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study
John R. Bergquist et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2016)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka et al.
LANCET (2016)
Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
Riccardo Casadei et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2015)
Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study
Ippei Matsumoto et al.
PANCREATOLOGY (2015)
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
Henriette Golcher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2015)
A Prospective Randomized Controlled Study Comparing Outcomes of Standard Resection and Extended Resection, Including Dissection of the Nerve Plexus and Various Lymph Nodes, in Patients With Pancreatic Head Cancer
Jin-Young Jang et al.
ANNALS OF SURGERY (2014)
National Assessment of Margin Status as a Quality Indicator after Pancreatic Cancer Surgery
Ryan P. Merkow et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma
Kenjiro Kimura et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery
Sohei Satoi et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2013)
The prognostic and predictive value of serum CA19.9 in pancreatic cancer
J. L. Humphris et al.
ANNALS OF ONCOLOGY (2012)
Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma
Teiichi Sugiura et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2012)
Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas Long-term results of a Japanese multicenter randomized controlled trial
Yuji Nimura et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)
Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy
Koichiro Tsutsumi et al.
PANCREATOLOGY (2012)
CA 19-9 LEVEL AS INDICATOR OF EARLY DISTANT METASTASIS AND THERAPEUTIC SELECTION IN RESECTED PANCREATIC CANCER
Tae Hyun Kim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
The Clavien-Dindo Classification of Surgical Complications Five-Year Experience
Pierre A. Clavien et al.
ANNALS OF SURGERY (2009)
Increased Levels of Both Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Reflect Postoperative Prognosis in Patients With Pancreatic Carcinoma
Kohei Shibata et al.
PANCREAS (2009)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Postoperative pancreatic fistula: An international study group (ISGPF) definition
C Bassi et al.
SURGERY (2005)
High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas
M Niedergethmann et al.
PANCREAS (2002)
Share Paper
